Immunome, Inc. (NASDAQ:IMNM) Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB lessened its stake in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) by 13.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 200,000 shares of the company's stock after selling 30,000 shares during the quarter. Handelsbanken Fonder AB owned about 0.32% of Immunome worth $2,124,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. Three Bridge Wealth Advisors LLC purchased a new stake in Immunome in the 4th quarter valued at $293,000. Stoneridge Investment Partners LLC purchased a new stake in Immunome in the 4th quarter valued at $123,000. Scharf Investments LLC purchased a new stake in Immunome in the 4th quarter valued at $471,000. Magnus Financial Group LLC raised its position in Immunome by 107.8% during the 4th quarter. Magnus Financial Group LLC now owns 53,536 shares of the company's stock worth $569,000 after buying an additional 27,777 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in Immunome by 6.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 24,565 shares of the company's stock worth $359,000 after buying an additional 1,520 shares during the last quarter. Hedge funds and other institutional investors own 44.58% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on IMNM. Stephens began coverage on shares of Immunome in a research report on Friday, November 8th. They set an "overweight" rating and a $30.00 price objective for the company. Wedbush restated an "outperform" rating and set a $33.00 price objective on shares of Immunome in a research report on Monday, January 13th. Finally, Piper Sandler cut their price objective on shares of Immunome from $23.00 to $21.00 and set an "overweight" rating for the company in a research report on Thursday, November 14th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Immunome currently has an average rating of "Buy" and a consensus price target of $28.60.

Remove Ads

Insider Transactions at Immunome

In related news, CEO Clay B. Siegall purchased 150,000 shares of the stock in a transaction dated Friday, January 31st. The shares were acquired at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the purchase, the chief executive officer now directly owns 669,636 shares in the company, valued at $5,189,679. This trade represents a 28.87 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 8.60% of the company's stock.

Immunome Trading Up 5.7 %

Shares of NASDAQ:IMNM traded up $0.51 on Friday, reaching $9.40. 893,838 shares of the company were exchanged, compared to its average volume of 952,383. Immunome, Inc. has a 1-year low of $8.55 and a 1-year high of $30.96. The firm has a market cap of $749.90 million, a price-to-earnings ratio of -1.16 and a beta of 1.90. The company has a 50-day moving average of $10.33 and a 200-day moving average of $12.18.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.